William Cooke, MD
Family Medicine · Austin, INNPI 1699749770
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,800 of the $76,369 with a category attached, or 75.7%. Viiv Healthcare Company accounts for 66.3% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $38,184 and has fallen 53.4% since, to $17,788 in 2025. Among family medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $247.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$51K
- AbbVie$23K
- GSK$1K
- Gilead$270
- Novo Nordisk$200
- Alkermes, Inc.$82
- plus $811 from 26 others
What the payments were for
- Consulting fees$3,9385%
- Speaking & faculty fees$57,80076%
- Travel & lodging$9,00012%
- Food & beverage$5,6027%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 108 | $50,657 |
| AbbVie(2 entities) | 110 | $23,065 |
| GSK | 10 | $1,285 |
| Gilead | 14 | $270 |
| Novo Nordisk | 15 | $200 |
| Alkermes, Inc. | 4 | $82 |
| Novartis | 4 | $77 |
| Merck | 4 | $73 |
| Amgen | 4 | $65 |
| EMD Serono, Inc. | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 3 | $48 |
| Vanda Pharmaceuticals Inc. | 2 | $46 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| Pfizer | 2 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Indivior Inc. | 2 | $26 |
| Tris Pharma Inc | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Medtronic | 1 | $17 |
| Medline Industries LP | 1 | $16 |
| Bayer | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Abbott | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,369 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 20 | $22,074 |
| NucyntaTapentadol Hcl | 11 | $14,967 |
| ProzacFluoxetine Hcl | 11 | $8,217 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $623 |
| Lidocaine | 12 | $482 |
| Gabapentin | 49 | $432 |
| Atorvastatin Calcium | 35 | $345 |
| Naltrexone Hcl | 11 | $345 |
| Lansoprazole | 12 | $306 |
| Fenofibrate | 12 | $277 |
| Ondansetron OdtOndansetron | 12 | $190 |
| Hydroxyzine Hcl | 23 | $144 |
| Fluticasone Propionate | 18 | $143 |
| Duloxetine Hcl | 18 | $130 |
| Trazodone Hcl | 16 | $125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $28 | $22,07420 claims |
| Collegium Pharmaceutical, Inc.Nucynta | $17 | $14,96711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Austin
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Anthony InzerelloEvansville$308K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
- Thomas KintanarFort Wayne$185K
- Jeffrey HiltzMuncie$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.